

Title (en)  
ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING ENGINEERED ANTIBODIES

Title (de)  
ANTI-PDGF-ANTIKÖRPER UND VERFAHREN ZUR HERSTELLUNG KONSTRUIERTER ANTIKÖRPER

Title (fr)  
ANTICORPS ANTI-PDGF ET PROCEDES DE PRODUCTION D'ANTICORPS MIS AU POINT

Publication  
**EP 1436329 A4 20050427 (EN)**

Application  
**EP 02775937 A 20020920**

Priority  
• US 0230086 W 20020920  
• US 32353701 P 20010920  
• US 32354401 P 20010920  
• US 37999402 P 20020513

Abstract (en)  
[origin: WO03025019A1] Methods of making and selecting engineered antibodies and/or antibody fragments provide maximized binding affinity for a predetermined target and minimized immunogenicity when such antibodies are administered to a target species. Libraries containing variants of the engineered antibodies are also provided. In particularly useful embodiments, anti-PGDF antibodies and compositions are produced which are useful in the treatment of various cancers.

IPC 1-7  
**C07K 16/00**; **C07K 16/28**; **C12N 15/00**; **A61K 39/395**

IPC 8 full level  
**A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/22** (2006.01); **C07K 16/26** (2006.01); **C07K 16/46** (2006.01); **C12N 15/09** (2006.01)

CPC (source: EP)  
**A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07K 16/22** (2013.01); **C07K 16/464** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/73** (2013.01)

Citation (search report)  
• [Y] US 6180370 B1 20010130 - QUEEN CARY L [US], et al  
• [X] WO 9924059 A1 19990520 - MASSACHUSETTS INST TECHNOLOGY [US], et al  
• [A] WO 9929888 A1 19990617 - SCRIPPS RESEARCH INST [US]  
• [Y] CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666  
• [X] BROECKER M ET AL: "Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line.", LIFE SCIENCES, 1998, vol. 63, no. 26, 1998, pages 2373 - 2386, XP002307362, ISSN: 0024-3205  
• [X] SHIMIZU S ET AL: "In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, no. 12, December 2000 (2000-12-01), pages 1285 - 951, XP002960893, ISSN: 0910-5050  
• [A] WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP004461859, ISSN: 0022-2836  
• See references of WO 03025019A1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)  
**WO 03025019 A1 20030327**; **WO 03025019 A8 20040401**; **WO 03025019 A9 20040506**; CA 2460587 A1 20030327; EP 1436329 A1 20040714; EP 1436329 A4 20050427; JP 2005512962 A 20050512

DOCDB simple family (application)  
**US 0230086 W 20020920**; CA 2460587 A 20020920; EP 02775937 A 20020920; JP 2003528864 A 20020920